These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Multiple myeloma and physical activity: a scoping review. Smith L; McCourt O; Henrich M; Paton B; Yong K; Wardle J; Fisher A BMJ Open; 2015 Nov; 5(11):e009576. PubMed ID: 26614625 [TBL] [Abstract][Full Text] [Related]
8. Smouldering multiple myeloma: To seek or not to seek? To treat or not to treat. That is the question. Vaxman I; Gatt ME Br J Haematol; 2024 Apr; 204(4):1141-1142. PubMed ID: 38429858 [TBL] [Abstract][Full Text] [Related]
9. Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. Boyle EM; Rosenthal A; Ghamlouch H; Wang Y; Farmer P; Rutherford M; Ashby C; Bauer M; Johnson SK; Wardell CP; Wang Y; Hoering A; Schinke C; Thanendrarajan S; Zangari M; Barlogie B; Dhodapkar MV; Davies FE; Morgan GJ; van Rhee F; Walker BA Leukemia; 2022 Feb; 36(2):591-595. PubMed ID: 34365473 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic performance of Hill E; Mena E; Morrison C; Dew A; Choyke P; Lindenberg L; Kazandjian D Br J Haematol; 2021 Apr; 193(1):125-128. PubMed ID: 32966607 [TBL] [Abstract][Full Text] [Related]
11. Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case. Chiecchio L; Dagrada GP; Protheroe RK; Stockley DM; Smith AG; Orchard KH; Cross NC; Harrison CJ; Ross FM; Haematologica; 2009 Jul; 94(7):1024-8. PubMed ID: 19454499 [TBL] [Abstract][Full Text] [Related]
13. Serum markers alone can define high-risk smouldering multiple myeloma: new insights from the Czech Myeloma Group model. Sørrig R Br J Haematol; 2020 Jul; 190(2):137-138. PubMed ID: 32220013 [No Abstract] [Full Text] [Related]
14. The difficult business of assessing new therapies for smouldering multiple myeloma. Zonder JA Br J Haematol; 2018 Aug; 182(4):463-464. PubMed ID: 29767407 [No Abstract] [Full Text] [Related]
15. Whole-body magnetic resonance imaging plus serological follow-up for early identification of progression in smouldering myeloma patients to prevent development of end-organ damage. Wennmann M; Goldschmidt H; Mosebach J; Hielscher T; Bäuerle T; Komljenovic D; McCarthy PL; Merz M; Schlemmer HP; Raab MS; Sauer S; Delorme S; Hillengass J Br J Haematol; 2022 Oct; 199(1):65-75. PubMed ID: 35608264 [TBL] [Abstract][Full Text] [Related]
16. Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma. Dalla Palma B; Marchica V; Pedrazzoni M; Accardi F; Notarfranchi L; Goldoni M; De Luca F; Costa F; Storti P; Toscani D; Sammarelli G; Bonomini S; Aversa F; Giuliani N Br J Haematol; 2018 Dec; 183(5):812-815. PubMed ID: 29143308 [No Abstract] [Full Text] [Related]
18. Effect of low-dose bortezomib on bone formation in smouldering multiple myeloma. Hildebrandt GC; Berno T; Gurule A; Mohan M; Yoon D; Salama M; Zangari M Br J Haematol; 2019 Jan; 184(2):308-310. PubMed ID: 29574687 [No Abstract] [Full Text] [Related]
19. Differentiation of benign monoclonal gammopathy and smouldering multiple myeloma from frank myeloma. Shimizu K; Ohnishi K; Kunii A Clin Exp Immunol; 1982 Dec; 50(3):596-600. PubMed ID: 6819908 [TBL] [Abstract][Full Text] [Related]
20. Survival in smouldering myeloma and symptomatic myeloma: Is there an emerging Will Rogers phenomenon? Chakraborty R Eur J Cancer; 2022 Sep; 172():234-236. PubMed ID: 35797760 [No Abstract] [Full Text] [Related] [Next] [New Search]